@article {1016091,
	title = {LONG-TERM OUTCOMES OF RITUXIMAB THERAPY IN PATIENTS WITH NONINFECTIOUS POSTERIOR UVEITIS REFRACTORY TO CONVENTIONAL IMMUNOSUPPRESSIVE THERAPY},
	journal = {Retina},
	volume = {38},
	number = {2},
	year = {2018},
	month = {2018 Feb},
	pages = {395-402},
	abstract = {PURPOSE: To assess long-term effectiveness of rituximab therapy for refractory noninfectious uveitis affecting the posterior segment. METHODS: Retrospective case series. Patients diagnosed with recalcitrant noninfectious posterior uveitis who were treated with rituximab intravenous infusions between 2010 and 2015 were included. Patients underwent best-corrected visual acuity testing and fluorescein angiography evidence of disk or vascular staining at 6, 12, 18, and 24 months. Patients had at least 24 months of follow-up. RESULTS: Eleven patients (21 eyes) with refractory posterior uveitis treated with intravenous rituximab were included. Nine (81.8\%) patients were female. Mean follow-up was 29.3 {\textpm} 7.8 months. rituximab was administered as complementary therapy because of previous inefficacy of other therapies in 7 (63.7\%) patients, and it was the only treatment in four (36.3\%) patients who did not tolerate other drugs. Inflammation signs by fluorescein angiography were controlled in nine (81.8\%) patients at the end of follow-up. Baseline best-corrected visual acuity was 20/80 (logarithm of the minimal angle of resolution 0.6 {\textpm} 0.4), and final best-corrected visual acuity was 20/40 (0.3 {\textpm} 0.5) (P = 0.005). No significant side effects were reported. CONCLUSION: Rituximab therapy was associated with stability and remission of recalcitrant noninfectious posterior uveitis in patients who did not tolerate or did not respond to other therapies.},
	issn = {1539-2864},
	doi = {10.1097/IAE.0000000000001563},
	author = {Lasave, Andres F and You, Caiyun and Ma, Lina and Abusamra, Khawla and Lamba, Neerav and Valdes Navarro, Manuel and Meese, Halea and Foster, C Stephen}
}
